Eptotermin alfa
Opgenra, Osigraft (eptotermin alfa) is a protein pharmaceutical. Eptotermin alfa was first approved as Osigraft on 2001-05-17. It has been approved in Europe to treat spondylolisthesis and tibial fractures. It is known to target bone morphogenetic protein receptor type-2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| wounds and injuries | D014947 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tibial fractures | D013978 | EFO_0003944 | S82.20 | — | — | — | 1 | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | 1 | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | — | — | 1 | — | 1 |
| Immune system diseases | D007154 | — | D89.9 | — | — | — | 1 | — | 1 |
| Nephrosclerosis | D009400 | EFO_1000041 | I12 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | 1 | — | — | 2 |
| Memory disorders | D008569 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 2 | 1 | — | — | — | 3 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 2 | 1 | — | — | — | 3 |
| Malocclusion | D008310 | — | M26.4 | — | 1 | — | — | 1 | 2 |
| Osteosarcoma | D012516 | — | — | 1 | 1 | — | — | — | 2 |
| Cataract | D002386 | EFO_0001059 | H26.9 | 1 | 1 | — | — | 1 | 2 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | 1 | — | — | — | 1 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | 1 | — | — | — | 1 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Oropharyngeal neoplasms | D009959 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
| Rhabdomyosarcoma | D012208 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spondylolisthesis | D013168 | EFO_0007493 | M43.1 | — | — | — | — | 3 | 3 |
| Edentulous jaw | D007575 | — | — | — | — | — | — | 1 | 1 |
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | — | 1 | 1 |
| Femur head necrosis | D005271 | — | — | — | — | — | — | 1 | 1 |
| Necrosis | D009336 | — | — | — | — | — | — | 1 | 1 |
| Intervertebral disc degeneration | D055959 | — | — | — | — | — | — | 1 | 1 |
| Joint diseases | D007592 | — | M12.9 | — | — | — | — | 1 | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 1 | 1 |
| Dyssomnias | D020920 | — | — | — | — | — | — | 1 | 1 |
| Parasomnias | D020447 | — | G47.5 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Eptotermin alfa |
| INN | eptotermin alfa |
| Description | Bone morphogenetic protein 7 or BMP7 (also known as osteogenic protein-1 or OP-1) is a protein that in humans is encoded by the BMP7 gene.
|
| Classification | Protein |
| Drug class | growth factors: bone morphogenetic proteins; growth factors: transforming growth factors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108594 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | IT063R5MY0 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
BMPR2
BMPR2
Organism
Homo sapiens
Gene name
BMPR2
Gene synonyms
PPH1
NCBI Gene ID
Protein name
bone morphogenetic protein receptor type-2
Protein synonyms
BMP type II receptor, BMP type-2 receptor, BMPR-II, Bone morphogenetic protein receptor type II, bone morphogenetic protein receptor, type II (serine/threonine kinase), type II activin receptor-like kinase, type II receptor for bone morphogenetic protein-4
Uniprot ID
Mouse ortholog
Bmpr2 (12168)
bone morphogenetic protein receptor type-2 (O35607)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,866 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use